Minerva Neurosciences, Inc. Operating Cash Flow
Minerva Neurosciences, Inc. (NERV) reported Operating Cash Flow of -$18.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$13.34M.
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.43M.
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$4.48M.
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.92M.
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$13.51M.
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$19.55M.
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$14.78M.
- Minerva Neurosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$24.65M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$18.77M 10-Q · filed 2026-08-07 | -$23.25M derived: sum of 3 quarters · filed 2026-08-07 | -$26.17M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$5.43M 10-Q · filed 2026-05-05 | -$9.91M derived: sum of 2 quarters · filed 2026-05-05 | -$12.82M derived: sum of 3 quarters · filed 2026-05-05 | -$14.87M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$7.40M derived: sum of 2 quarters · filed 2026-03-11 | -$9.44M derived: sum of 3 quarters · filed 2026-08-07 | -$13.51M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.96M derived: sum of 2 quarters · filed 2026-08-07 | -$9.03M 10-Q · filed 2025-11-05 | -$14.20M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$6.11M 10-Q · filed 2026-08-07 | -$11.28M derived: sum of 3 quarters · filed 2026-08-07 | -$15.63M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$4.07M 10-Q · filed 2026-05-05 | -$9.24M derived: sum of 2 quarters · filed 2026-05-05 | -$13.59M derived: sum of 3 quarters · filed 2026-05-05 | -$17.53M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$9.52M derived: sum of 2 quarters · filed 2026-03-11 | -$13.46M derived: sum of 3 quarters · filed 2026-03-11 | -$19.55M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$4.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$8.29M derived: sum of 2 quarters · filed 2025-11-05 | -$14.38M 10-Q · filed 2025-11-05 | -$20.38M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$10.03M 10-Q · filed 2025-08-14 | -$16.02M derived: sum of 3 quarters · filed 2025-08-14 | -$20.83M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$6.09M 10-Q · filed 2025-05-13 | -$12.09M derived: sum of 2 quarters · filed 2025-05-13 | -$16.89M derived: sum of 3 quarters · filed 2025-05-13 | -$20.76M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$10.80M derived: sum of 2 quarters · filed 2025-02-25 | -$14.67M derived: sum of 3 quarters · filed 2025-02-25 | -$14.78M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$4.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$8.68M derived: sum of 2 quarters · filed 2024-11-05 | -$8.79M 10-Q · filed 2024-11-05 | -$12.90M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$3.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$3.99M 10-Q · filed 2024-08-06 | -$8.10M derived: sum of 3 quarters · filed 2024-08-06 | -$17.63M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$115.41K 10-Q · filed 2024-05-01 | -$4.23M derived: sum of 2 quarters · filed 2024-05-01 | -$13.76M derived: sum of 3 quarters · filed 2024-05-01 | -$18.95M derived: sum of 4 quarters · filed 2024-05-01 |
| 2022-12-31 | -$4.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$13.64M derived: sum of 2 quarters · filed 2024-02-22 | -$18.84M derived: sum of 3 quarters · filed 2024-02-22 | -$24.65M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$9.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$14.73M derived: sum of 2 quarters · filed 2023-11-07 | -$20.54M 10-Q · filed 2023-11-07 | -$25.37M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$5.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$11.00M 10-Q · filed 2023-08-01 | -$15.83M derived: sum of 3 quarters · filed 2023-08-01 | -$24.46M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | -$5.81M 10-Q · filed 2023-05-15 | -$10.64M derived: sum of 2 quarters · filed 2023-05-15 | -$19.27M derived: sum of 3 quarters · filed 2023-05-15 | -$25.19M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$4.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$13.46M derived: sum of 2 quarters · filed 2023-03-08 | -$19.38M derived: sum of 3 quarters · filed 2023-03-08 | -$24.60M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$8.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$14.55M derived: sum of 2 quarters · filed 2022-11-09 | -$19.77M 10-Q · filed 2022-11-09 | -$26.93M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$5.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$11.14M 10-Q · filed 2022-08-09 | -$18.30M derived: sum of 3 quarters · filed 2022-08-09 | -$28.17M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$5.22M 10-Q · filed 2022-05-04 | -$12.38M derived: sum of 2 quarters · filed 2022-05-04 | -$22.25M derived: sum of 3 quarters · filed 2022-05-04 | -$29.84M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$7.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$17.03M derived: sum of 2 quarters · filed 2022-03-01 | -$24.62M derived: sum of 3 quarters · filed 2022-03-01 | -$33.82M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$9.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$17.46M derived: sum of 2 quarters · filed 2021-11-08 | -$26.66M 10-Q · filed 2021-11-08 | -$40.84M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$7.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | -$16.79M 10-Q · filed 2021-08-02 | -$30.97M derived: sum of 3 quarters · filed 2021-08-02 | -$40.49M derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-03-31 | -$9.20M 10-Q · filed 2021-05-12 | -$23.38M derived: sum of 2 quarters · filed 2021-05-12 | -$32.90M derived: sum of 3 quarters · filed 2021-05-12 | -$43.03M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$14.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | -$23.70M derived: sum of 2 quarters · filed 2021-03-08 | -$33.83M derived: sum of 3 quarters · filed 2021-03-08 | -$43.43M 10-K · filed 2021-03-08 |
| 2019-09-30 | -$9.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | -$19.65M derived: sum of 2 quarters · filed 2020-11-02 | -$29.25M 10-Q · filed 2020-11-02 | -$39.05M derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-06-30 | -$10.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | -$19.73M 10-Q · filed 2020-08-03 | -$29.53M derived: sum of 3 quarters · filed 2020-08-03 | -$39.51M derived: sum of 4 quarters · filed 2020-08-03 |
| 2019-03-31 | -$9.60M 10-Q · filed 2020-05-04 | -$19.40M derived: sum of 2 quarters · filed 2020-05-04 | -$29.39M derived: sum of 3 quarters · filed 2020-05-04 | -$40.61M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | -$9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$19.78M derived: sum of 2 quarters · filed 2020-03-09 | -$31.01M derived: sum of 3 quarters · filed 2020-03-09 | -$41.94M 10-K · filed 2020-03-09 |
| 2018-09-30 | -$9.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$21.21M derived: sum of 2 quarters · filed 2019-11-04 | -$32.14M 10-Q · filed 2019-11-04 | -$41.05M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | -$11.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$22.16M 10-Q · filed 2019-08-05 | -$31.07M derived: sum of 3 quarters · filed 2019-08-05 | -$6.18M derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | -$10.93M 10-Q · filed 2019-05-06 | -$19.84M derived: sum of 2 quarters · filed 2019-05-06 | $5.05M derived: sum of 3 quarters · filed 2019-05-06 | |
| 2017-12-31 | -$8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $15.98M derived: sum of 2 quarters · filed 2019-03-12 | $3.09M 10-K · filed 2019-03-12 | |
| 2017-09-30 | $24.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $12.00M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | -$12.89M 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |